Business / Corporate | ANALYSIS Apr 26, 2018
Shire bid marks Takeda's latest and biggest push for global status
by Sam Nussey
Takeda Pharmaceutical Co. Ltd..'s $64 billion bid for London-listed rare-disease specialist Shire PLC bolsters its credentials as Japan's most outward-facing drugs firm, a mold-breaking image that has been more than a decade in the making. Under CEO Christophe Weber and his predecessor, Yasuchika Hasegawa, Takeda ...
